Incyte (INCY) Operating Income Growth (1y) (2011 - 2026)

Incyte (INCY) Operating Income Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -24.89%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 2,150.96%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 80.62%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 8.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 145.20%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Incyte 23.64 Bn 19.62 Bn 1.17 Bn 46.77%

Historic Data

Download Data
DateValue
Mar 31, 2026 46.77%
Dec 31, 2025 11.39%
Sep 30, 2025 203.60%
Jun 30, 2025 210.91%
Mar 31, 2025 123.26%
Dec 31, 2024 61.00%
Sep 30, 2024 -31.96%
Jun 30, 2024 -346.74%
Mar 31, 2024 271.01%
Dec 31, 2023 167.17%
Sep 30, 2023 55.16%
Jun 30, 2023 -23.84%
Mar 31, 2023 -78.75%
Dec 31, 2022 -36.70%
Sep 30, 2022 -41.22%
Jun 30, 2022 80.66%
Mar 31, 2022 17.96%
Dec 31, 2021 -32.57%
Sep 30, 2021 4,320.02%
Jun 30, 2021 -38.97%